Two recent studies have independently identified macropinocytosis, a nutrient procurement pathway whereby cancer cells take up extracellular fluid droplets containing proteins and other macromolecules, as a promising new therapeutic target for pancreatic ductal adenocarcinoma (PDAC).
Single-cell genomic analysis has shown that mutations in the KRAS oncogene co-opt a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells, initiating pancreatic ductal adenocarcinoma, Chinese researchers reported in the November 3, 2020, edition of Nature Cancer.
